Muscle Wasting

Atrix Acquires Novel Growth Promoting Peptide

Published in AIDS Weekly, October 15th, 2001

Atrix Laboratories Inc. (ATRX) has exercised an option to license a novel compound, human growth hormone releasing peptide-1 (GHRP-1), from Tulane University Health Sciences Center. Atrix will develop GHRP-1 utilizing its sustained-release delivery technology, Atrigel.

"Licensing our first new chemical entity represents a new step forward for Atrix," said David R. Bethune, chairman and chief executive officer at Atrix. "Our goal is to deliver a unique, physiologically relevant growth promoting compound using our Atrigel drug delivery technology. With a recently developed sustained-release formulation, we believe we will be able to capitalize on this opportunity and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-10-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry